RECORD4: More impressive data on rivaroxaban in VTE prevention

Previous | Next

Latest post 07-10-2008 8:57 AM by Rogerven. 2 replies.

06-07-2008 6:54 PM

Rogerven
Joined on 04-17-2004
Posts 709
Points 9,496

RECORD4: More impressive data on rivaroxaban in VTE prevention

Considering the need to shorten lenght of stays, Rivaroxaban, indeed will likely be embraced immediately as soon as it becomes available.

RECORD4: More impressive data on rivaroxaban in VTE prevention

June 6, 2008

Sue Hughes

Nice, France- The new oral anticoagulant rivaroxaban (Johnson & Johnson/Bayer) showed superior efficacy compared with the US-approved dosing regimen of enoxaparin in preventing venous thromboembolism (VTE) in patients who had undergone total-knee-replacement surgery in the RECORD4 trial [1].

Rivaroxaban is one of several potential new oral anticoagulants in development. First indications will be in preventing VTE after surgery, but these agents are also being developed as replacements for warfarin for the prevention of stroke in atrial-fibrillation patients and for the treatment of acute coronary syndromes.

http://www.theheart.org/article/872775.do

Roger Ven Torres, M.D. http://www.wapcp.org/ Praxis user since 2000

Post Points: 20

06-09-2008 12:09 AM In reply to

alborg
Joined on 07-05-2004
USA
Posts 4,147
Points 58,309

Re: RECORD4: More impressive data on rivaroxaban in VTE prevention

Contact

Rivaroxaban reminds me of Exenta, the AstraZenica anticoagulant that the FDA nixed at the last moment due to findings of hepatic inflamation. It seemed that the drug was a shoe-in, but on 11/2006 it was suddenly denied approval.

So far it looks like rivaroxaban's liver toxicity is very infrequent. I hope that it gets approved...

Al Borges, M.D.

● Oncologist in a Small Group Practice in Virginia

● My website URL: http://msofficeemrproject.com/

Post Points: 20

07-10-2008 8:57 AM In reply to

Rogerven
Joined on 04-17-2004
Posts 709
Points 9,496

Re: RECORD4: More impressive data on rivaroxaban in VTE prevention

Contact

RECORD1, 2 and 3 rivaroxaban trials published

July 1, 2008 | Sue Hughes

Download slides

The sidebar on the pooled analysis of RECORD1, 2, and 3 has been added to this story, which was originally published June 23, 2008.

Hamilton, ON - Three trials of the new oral anticoagulant rivaroxaban, showing impressive results in the prevention of venous thromboembolism (VTE) in patients undergoing orthopedic surgery, were published last week. A pooled analysis from RECORD1, 2, and 3 has also shown superiority of rivaroxaban over enoxaparin in preventing VTE without increasing bleeding.

The RECORD1 and 3 trials are published in the June 26, 2008, issue of the New England Journal of Medicine [1,2], while the RECORD2 trial is published online in the Lancet on June 25, 2008 [3]. All three trials have been presented previously (and reported by heartwire) at various medical meetings. A fourth similar trial (RECORD4) was presented earlier this month at the 2008 Congress of the European Federation of National Associations of Orthopaedics and Traumatology.